Publications by authors named "H Shida"
This systematic review and meta-analysis evaluated the effects of enhanced rehabilitation initiated after hospital discharge on the quality of life (QOL) in survivors of critical care. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) procedure. MEDLINE, CENTRAL, Ichushi, Embase, PEDro, and Cumulated Index to Nursing and Allied Health Literature (CINAHL) databases and the International Clinical Trials Registry Platform and ClinicalTrials.
View Article and Find Full Text PDF: We developed a multistage vaccine using a heterologous prime-boost immunization strategy. This involved priming with a highly attenuated, replication-competent vaccinia virus strain LC16m8Δ (m8Δ) and boosting with adeno-associated virus type 1 (AAV1). This approach demonstrated 100% efficacy in both protection and transmission-blocking in a murine model.
View Article and Find Full Text PDFArticle Synopsis
- * In this research, modifications to specific amino acid positions (Ala5 and Gly9) were shown to significantly influence the secondary structure and binding efficacy of 15-IgBP to immunoglobulin G (IgG).
- * The study identified crucial structural features that can enhance peptide affinity for IgG and discovered new sites for potential attachments in developing antibody-drug conjugates, leading to four peptides with strong binding potential (K = 4.24-5.85 nM).
Among spp. responsible for human malaria, ranks as the second most prevalent and has the widest geographical range; however, vaccine development has lagged behind that of , the deadliest species. Recently, we developed a multistage vaccine for based on a heterologous prime-boost immunization regimen utilizing the attenuated vaccinia virus strain LC16m8Δ (m8Δ)-prime and adeno-associated virus type 1 (AAV1)-boost, and demonstrated 100% protection and more than 95% transmission-blocking (TB) activity in the mouse model.
View Article and Find Full Text PDFObjective: Prescription trends and patterns of anti-COVID-19 drugs in hospitalized patients were examined based on real world data to understand the use of anti-COVID-19 drugs in clinical practice in Japan.
Design: The longitudinal and cross-sectional study was conducted utilizing data from January 1, 2019 to December 31, 2021 of the MID-NET® medical information database, which stored the electronic medical records, administrative claim data, and diagnosis procedure combination data of patients in Japan.
Participants: Hospitalized patients with a COVID-19-related diagnosis who received at least one anti-COVID-19 drug between April 1, 2020 and December 31, 2021.